Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. - Wikidata - awgldk - TriplyDB

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

http://www.wikidata.org/entity/Q33410481

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Novel agents in the treatment of multiple myeloma: a review about the future Clinical use and applications of histone deacetylase inhibitors in multiple myeloma Treatment of relapsed and refractory multiple myeloma European perspective on multiple myeloma treatment strategies in 2014 Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Clinical use of proteasome inhibitors in the treatment of multiple myeloma Novel therapeutic strategies for multiple myeloma Trial Watch: Proteasomal inhibitors for anticancer therapy Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma.Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.Update on the optimal use of bortezomib in the treatment of multiple myeloma The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Multiple myeloma in the marrow: pathogenesis and treatments.Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.The role of epigenetics in the biology of multiple myeloma.Current and potential epigenetic targets in multiple myeloma.Salvage therapy of multiple myeloma: the new generation drugs.Bortezomib-induced peripheral neurotoxicity: an update.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Panobinostat: a review of trial results and future prospects in multiple myeloma.Treatment-related symptom management in patients with multiple myeloma: a review.Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

P2860

Q26740359-CE2A2994-8205-4615-9B5C-C5341EB70B7F Q26745924-D66E4301-C03E-46F6-8D28-BD7D52EB5594 Q26745930-125C35C2-4158-460A-A099-AA663E1E9033 Q26749180-AB94A0C6-A44B-424B-9DEF-4234284ACCBB Q27005966-F6E8EB97-37A5-47DE-8FE7-5E73059EDD75 Q27026478-E47EC8DB-B28D-4A92-B354-6C6B1C5AD8A3 Q28067148-FD3B8B1D-F507-44AE-BD84-370BD2D576E0 Q28069789-EDD05E60-CC02-4B08-89A5-3FAEDDB09156 Q28080999-6794EDC8-ACE1-4E1C-8765-70195C8F8732 Q28081590-47DFAB72-623F-422A-8AF2-EB2B20F058BC Q28082910-AD3E62F9-203D-4BD1-8333-D7D2DAA654D2 Q30802505-E3E8904C-5890-46AA-9095-201864DF392D Q33423168-98028D40-15C2-464C-9A7D-8869BD5D8AAA Q33427979-C874FAC8-FFBA-4E94-A536-57E04EC04DC3 Q33429115-6909AC6B-998C-4D37-A809-93B8E17AB3BD Q33436890-68945FD3-B804-4A49-955E-595F37803881 Q33440007-4804D1A8-0AA7-4B93-B691-16780CE8BE7D Q34218976-6D7D52EF-6543-4D25-AF07-30E2F0BB9464 Q34372977-A0FC76E1-DF45-4256-98F6-D1311D97C453 Q34798095-2E24DBB0-8767-44CC-B662-E222CE574AFA Q34984542-AE7F9891-4A66-464C-8C94-6AD283DCF357 Q35726371-658625EC-A1EA-4FEF-8A02-011D2F36B04B Q35764582-B542BC15-4DF7-48DB-8A1A-7E70CC7A38EC Q36145310-FA891B0A-8A3B-4BF7-BA9A-2EFE56C519E3 Q36178810-131A4D96-1843-46F0-9B37-763E5CCFCD18 Q36544516-19A3D9DC-18CC-4E35-8747-6557405EF933 Q36725401-3B674D1A-13D9-4081-B2F5-BF2A9B9F987E Q36848015-B23CF2A8-B444-4D9B-BBD0-D9E3DD10E7D3 Q37199772-7F2C1173-D95D-48BB-AD60-551AEEFC15F8 Q37705920-749BE207-91DC-4A5E-B107-A04E738DD6C2 Q37737800-C4A95988-2E37-4B43-9274-38559E41F34D Q38208520-B3004BC3-AF66-4C77-9887-E07E30A0C6A8 Q38210475-58CCBF6B-A4E3-460F-BE17-A2E0B11B135C Q38223433-E7E94C65-3016-4231-A7A8-383606F53FB1 Q38234733-69520B83-9259-4A1C-B3E1-42001BAB0627 Q38255333-F6BAC1A1-800A-41FE-8B3D-FF5AD5CA9B5E Q38269612-8224D929-601A-4F20-A640-E07CB13B1181 Q38342281-D98F3234-6FDC-453E-8ADD-E4C70C695430 Q38360962-269C2611-6436-455E-A1A5-28484BFC4AFB Q38542092-2CF015A1-CC25-46CE-9EA0-13E7BC5AE32A

P2860

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

http://www.wikidata.org/entity/Q33410481

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Vorinostat or placebo in combi ...... andomised, double-blind study.

@ast

Vorinostat or placebo in combi ...... andomised, double-blind study.

@en

type

label

Vorinostat or placebo in combi ...... andomised, double-blind study.

@ast

Vorinostat or placebo in combi ...... andomised, double-blind study.

@en

prefLabel

Vorinostat or placebo in combi ...... andomised, double-blind study.

@ast

Vorinostat or placebo in combi ...... andomised, double-blind study.

@en

P1433

Q33410481-AB2267CA-9E39-440A-8839-D4685145290D

P1476

Q33410481-CB82D2FD-6936-4679-9A26-852F4FF5EDA6

P2093

Q33410481-0850D5D5-8E42-40DF-A074-CC8147F79451

Q33410481-29FB1857-E754-450A-B3A8-037EDCC00A97

Q33410481-32ED0AD1-14A0-4A75-B276-DEA1023F6CDC

Q33410481-3F74CCAF-5B9C-44FB-9DA8-E87BBC89A3F4

Q33410481-477AEEB5-FA66-4CCB-A553-86F37427F68F

Q33410481-5172B441-CC3B-42F3-82F0-C35EE5DA7C3F

Q33410481-58217D30-7E9C-4A77-8344-55686A0FEAD0

Q33410481-5FE31501-5180-45E7-B291-0B5B6C693DE7

Q33410481-66C2337D-CAAF-45EF-9AB5-31E101CFD12E

Q33410481-98647A03-9A03-4BA3-86DB-BD2EE8733C9F

P304

Q33410481-156FCEAF-12C3-4B2B-915E-428CAA5CC59E

P31

Q33410481-49E3B432-0F9A-4C97-808A-29E08AD9CCCA

P356

Q33410481-BBAAE7DB-583E-4DEE-B850-ED1BA64F6C5A

P433

Q33410481-7710DB96-86AD-49E4-BD6A-B344D358E92D

P478

Q33410481-F5E53124-5F3B-4AF5-B149-551AA5ADAD33

P50

Q33410481-12346D3A-57AB-4825-80DF-5C080C84C0B7

Q33410481-2E4F625E-D911-4DC1-A675-B6ACDDAA8114

Q33410481-4B971A2C-9671-4792-A4CE-69FDF1695DE4

Q33410481-8983E118-E19E-400A-B134-81E6756999BC

Q33410481-8E8C1B34-D238-49CD-9344-8833C549B170

Q33410481-B8F433F1-E006-4299-8DC5-B75DA3453DB4

Q33410481-BD1642A7-2635-406F-A2CE-7FA65E038BB4

Q33410481-D1F30554-EE9C-4DAF-B67F-D2230B13C3A7

P577

Q33410481-D5AE27B0-3449-4247-A047-03F94E9D5CE3

P698

Q33410481-26C64917-1F23-457E-8AF2-DA7AFF7C2E6B

P921

Q33410481-0F95D59D-B4A0-49F9-9848-98F495EDAE66

Q33410481-9632C3CC-ECF3-45A4-9FA9-B8375C7708F9

P356

S1470-2045(13)70398-X

P1433

The Lancet Oncology

P1476

Vorinostat or placebo in combi ...... andomised, double-blind study.

@en

P2093

Andrew Spencer

http://www.w3.org/2001/XMLSchema#string

Catherine Williams

http://www.w3.org/2001/XMLSchema#string

David S Siegel

http://www.w3.org/2001/XMLSchema#string

Hilary Blacklock

http://www.w3.org/2001/XMLSchema#string

Jennifer Houp

http://www.w3.org/2001/XMLSchema#string

Joseph E Eid

http://www.w3.org/2001/XMLSchema#string

Junyuan Qi

http://www.w3.org/2001/XMLSchema#string

Laura Rosinol

http://www.w3.org/2001/XMLSchema#string

Linda Sun

http://www.w3.org/2001/XMLSchema#string

Scott Vuocolo

http://www.w3.org/2001/XMLSchema#string

P304

1129-1140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(13)70398-X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Goldschmidt

Meletios A. Dimopoulos

Kenneth C Anderson

Antonio Palumbo

P577

2013-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24055414

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial